Evidence map›Paper›PMID 39431098›Full record

ArticleACS omega2024

Structure-Based Engineering of Monoclonal Antibodies for Improved Binding to Counteract the Effects of Fentanyl and Carfentanil.

Justas Rodarte, Carly Baehr, Dustin Hicks, Morgan McGovern, Yue Zhang, Pedro Silva-Ortiz, Bryan Hannon, Sowmya Duddu, Marie Pancera, Marco Pravetoni

Abstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. An antifentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs.The Journal of pharmacology and experimental therapeutics · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Justas RodarteVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington 98109, United States.
Carly BaehrDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, United States.ORCID https://orcid.org/0000-0002-3395-6776
Dustin HicksDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, United States.
Morgan McGovernVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington 98109, United States.
Yue ZhangDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, United States.
Pedro Silva-OrtizDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, United States.
Bryan HannonVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington 98109, United States.
Sowmya DudduVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington 98109, United States.
Marie PanceraVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington 98109, United States.
Marco PravetoniDepartment of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle, Washington 98195, United States.

Funding

User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI MARC ALLAIRE · 2017 to 2026
$28.6M
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine ComponentsUG3DA047711 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI COMER, SANDRA D, PRAVETONI, MARCO · 2018 to 2019
$9.4M
Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trialsUG3DA057850 · NIDA · UNIVERSITY OF WASHINGTON · PI COMER, SANDRA D, PRAVETONI, MARCO · 2022 to 2022
$8.3M
Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trialsUH3DA057850 · NIDA · UNIVERSITY OF WASHINGTON · PI SANDRA D. COMER, Marco Pravetoni · 2025 to 2026
$7.0M
Antibody-based countermeasures against fentanyl and its analoguesU01DA051658 · NIDA · UNIVERSITY OF WASHINGTON · PI PRAVETONI, MARCO · 2020 to 2022
$2.4M
Pilatus 6mS10OD021832 · OD · UNIVERSITY OF CALIFORNIA BERKELEY · PI ADAMS, PAUL DAVID · 2016 to 2016
$980k
Immunoprofiling of Opioid Use Disorder Patients to inform structure-guided design of opioid-specific monoclonal antibodiesF31DA059261 · NIDA · UNIVERSITY OF MINNESOTA · PI ZHANG, YUE · 2023 to 2024
$71k
NIDA NIH HHS F31 DA059261NIDA NIH HHS U01 DA051658NIDA NIH HHS UG3 DA047711NIDA NIH HHS UG3 DA057850NIDA NIH HHS UH3 DA057850NIGMS NIH HHS P30 GM124169NIH HHS S10 OD021832
6 · The paper itself

Abstract

The opioid overdose epidemic is a growing and evolving public health crisis fueled by the widespread presence of fentanyl and fentanyl analogues (F/FAs) in both street mixtures and counterfeit pills. To expand current treatment options, drug-targeting monoclonal antibodies (mAbs) offer a viable therapeutic for both pre- and postexposure clinical scenarios. This study reports the isolation,

Identifiers

PMID39431098
PMCPMC11483391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.